Clinical Trial Update: Safety Study of a Cell Penetrating Peptide (p28) to Treat Solid Tumors That Resist Standard Methods of Treatment [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating the cell-penetrating peptide p28 for solid tumors resistant to standard therapies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• p28 (p28)

Snippet

Sponsor: Dr. Tapas K. Das Gupta | Conditions: Refractory Solid Tumors | Phase 1 | Status: COMPLETED